Review of clinical practice guidelines on the use of procalcitonin in infections
| Autor: | Merja Kokki, Kari Pulkki, Hannu Kokki, Sari Hämäläinen, Benita Tujula |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty Web of science 030106 microbiology Procalcitonin Diagnosis Differential 03 medical and health sciences 0302 clinical medicine Sepsis Antibiotic therapy parasitic diseases medicine Humans 030212 general & internal medicine Practice Patterns Physicians' Intensive care medicine Respiratory Tract Infections General Immunology and Microbiology business.industry Bacterial Infections Pneumonia General Medicine bacterial infections and mycoses National guideline Anti-Bacterial Agents Community-Acquired Infections Clinical Practice Infectious Diseases Practice Guidelines as Topic Biomarker (medicine) business Biomarkers hormones hormone substitutes and hormone antagonists |
| Zdroj: | Infectious Diseases. 52:227-234 |
| ISSN: | 2374-4243 2374-4235 |
| Popis: | Background: Procalcitonin is a biomarker that can be used to diagnose bacterial infection and monitor treatment. Clinical practice guidelines are evidence-based recommendations by experts that aim to aid decision-making. In this systematic review, we searched for clinical practice guidelines and evaluated recommendations given regarding use of procalcitonin.Methods: Four biomedical databases (PubMed, Scopus, Cochrane Database and Web of Science) and various national medical sites were searched for clinical practice guidelines. Guidelines that mentioned procalcitonin were included in the review.Results: Seventeen guidelines were included. The earliest were published in 2009 and the latest in 2018. A majority (12/17) recommended use of procalcitonin or stated that it can be useful. One national guideline did not recommend procalcitonin, stating that there is no need for any biomarkers in diagnostics of community-acquired pneumonia in adults. Four guidelines stated no evidence to recommend or not recommend procalcitonin use. Thirteen of the guidelines commented on other concomitant or alternate biomarkers, mainly C-reactive protein. Five guidelines suggested decision limits for procalcitonin. None took a stand on how often procalcitonin should be analysed, and if it should be used as a single or as multiple measurements.Conclusions: One international and 11 national clinical practice guidelines endorse the use of procalcitonin in differential diagnosis of bacterial infections and/or to monitor antibiotic therapy. However, the evidence for or against the use of procalcitonin is weak. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|